8-K: Waters and BD Announce $17.5 Billion Combination of Life Science and Diagnostics Businesses

Becton, Dickinson and Company and Waters Corporation have entered into a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a $17.5 billion Reverse Morris Trust transaction, creating a new life science and diagnostics leader.

Summary

• Becton, Dickinson and Company (BD) and Waters Corporation announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion.
• The combined company is expected to have pro forma 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion.
• The transaction is anticipated to generate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three post-closing and $290 million of revenue synergies by year five.
• BD shareholders are expected to own approximately 39.2% of the combined company, while existing Waters shareholders are expected to own approximately 60.8%.
• BD will receive a cash distribution of approximately $4 billion prior to the completion of the combination, subject to adjustment.
• Waters is expected to assume approximately $4 billion of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing.
• The transaction is expected to be generally tax-free for U.S. federal income tax purposes to BD and BD's shareholders.
• The combined company will operate under the Waters name, retain its NYSE listing (WAT), and maintain its headquarters in Milford, Mass.
• The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to regulatory approvals, Waters shareholder approval, and other customary closing conditions.
• The 'New BD' (post-spin) is projected to have fiscal year 2024 revenue of approximately $17.8 billion and a $70+ billion addressable market expected to grow at approximately 5%, with over 90% consumables revenue.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook on the strategic and financial benefits of the transaction for both Waters and the 'New BD', emphasizing significant synergies, market expansion, and strong financial projections. Risks are disclosed as legally required but do not overshadow the overwhelmingly optimistic tone regarding value creation.

Positives

• The transaction creates an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook.
• It doubles Waters' total addressable market to approximately $40 billion, with an estimated 5-7% annual growth.
• The combined company is expected to achieve approximately $345 million in annualized EBITDA synergies by 2030, comprising $200 million in cost synergies by year three and $290 million in revenue synergies by year five.
• Over 70% of the combined company's revenue is expected to be annually recurring, with over 80% coming from iconic market-leading brands.
• The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
• The combined company is projected to deliver mid-to-high single-digit revenue growth and mid-teens annualized adjusted EPS growth between 2025 and 2030.
• BD's Biosciences & Diagnostic Solutions business brings strong leadership in immunology, cancer research, flow cytometry, microbiology, and infectious disease diagnostics.
• Waters' proven execution model is expected to unlock the full potential of BD's Biosciences & Diagnostic Solutions business through systematized instrument replacement, service plan attachment, e-commerce adoption, and new product launches.
• The transaction enhances BD's strategic focus as a leading medical technology company, allowing for continued investment in its innovation pipeline and operational excellence.
• BD's commitment to use at least half of the $4 billion cash proceeds for share repurchases enhances its capital allocation framework and shareholder returns.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise, potentially leading to prohibition, delay, or refusal of approval by governmental entities, or requiring conditions, limitations, or restrictions.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected by Waters, BD, and SpinCo, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including synergies, may occur due to delays in completion or integration of businesses.
• The combined company's ability to implement its business strategy may be challenged.
• Difficulties and delays may arise in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel is a risk.
• Any event could occur that gives rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations in connection with the proposed transaction may affect its timing or occurrence or result in significant costs of defense, indemnification, and liability.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined entity.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs could affect outcomes.
• Actions by third parties, including government agencies, pose a risk.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty may arise in separating the business of SpinCo from the other businesses of BD.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction, or other effects on relationships with employees, customers, suppliers, or other counterparties, are risks.
• The announcement or consummation of the proposed transaction could have a negative effect on the market price of the capital stock of Waters and BD or on Waters and BD's operating results.

Future Outlook

The combined company is expected to deliver an industry-leading financial outlook with mid-to-high single-digit revenue growth, approximately 500 basis points of adjusted operating margin expansion, and mid-teens annualized adjusted EPS growth expected over five years (2025-2030). By 2030, the pro forma combined company is expected to achieve approximately $9 billion in revenue, $3.3 billion in adjusted EBITDA, and an adjusted operating margin of 32%. The transaction is expected to be accretive to adjusted EPS in the first year post-closing. The 'New BD' is positioned for sustained success with a mid-single-digit growth profile, supported by attractive and growing end-markets and a best-in-class consumables revenue profile of over 90%.

Management Comments

• Flemming Ornskov, M.D., M.P.H., Chairman, Waters, stated: "This transaction marks a pivotal milestone in Waters' transformation journey as we embark on a new chapter of growth and value creation. Combining with BD's Biosciences & Diagnostic Solutions business is an excellent strategic fit with complementary strengths, and we are confident this combination will accelerate our strategy and deliver substantial nearand long-term value to our shareholders."
• Udit Batra, Ph.D., President and Chief Executive Officer, Waters, commented: "We see tremendous opportunity to immediately apply our expertise in instrument replacement, service plan attachment, and eCommerce expansion, and realize the full potential of the flow cytometry and specialty diagnostics portfolios. The combination doubles our accessible market to approximately $40 billion and allows us to accelerate value creation in multiple high-growth adjacencies."
• Tom Polen, Chairman, CEO and President, BD, said: "We are bringing together complementary portfolios and channels that create an industry-leading life science and diagnostics company. We see an incredible opportunity to leverage both companies' commitments to unparalleled innovation, technology, and commercial presence to serve attractive high-growth end-markets, while simultaneously unlocking multiple new growth vectors."
• Tom Polen also noted: "This transaction is an important milestone for BD, as it enhances our strategic focus as a leading medical technology company. BD is committed to unlocking long-term value through continued investment in our strong innovation pipeline, and operational and commercial excellence that will drive durable and profitable growth."

Industry Context

This transaction represents a significant strategic move within the life science tools and diagnostics industry, creating a new leader focused on regulated, high-volume testing. It reflects a broader industry trend towards specialization and the creation of pure-play entities to unlock value and accelerate growth in specific high-growth adjacencies such as bioseparations, bioanalytical characterization, and multiplex diagnostics. By combining Waters' expertise in liquid chromatography and mass spectrometry with BD's strengths in flow cytometry and diagnostic solutions, the new entity aims to capture a larger share of the expanding $40 billion total addressable market, leveraging complementary technologies and established market presence.

Comparison to Industry Standards

• The combined company is expected to deliver an 'industry-leading financial outlook' with mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth, suggesting performance superior to typical industry averages.
• Waters' standalone adjusted EBITDA margin of 31% (CY-24) is noted as significantly higher than the 'WAT Peer Avg' of 27% (peers include A, AVTR, DHR, RVTY, TMO).
• Waters' standalone Free Cash Flow as % of Revenue of 37% (CY-24) is also substantially higher than the 'WAT Peer Avg' of 18%.

Management Changes

Corporate Governance

Legal Proceedings

• The risk that stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders (BD): Expected to benefit from ownership in the combined company, participation in transaction synergies and growth opportunities, and enhanced capital allocation including share repurchases from the $4 billion cash distribution.
• Shareholders (Waters): Expected to benefit from significant market expansion, substantial cost and revenue synergies, and an industry-leading financial outlook for the combined entity.
• Employees (BD Biosciences & Diagnostic Solutions): Waters offers a cultural fit for associates to flourish and continue innovation, though there is a risk of inability to retain key personnel.
• Employees (Waters): Integration of new business and colleagues.
• Customers: Expected to benefit from complementary technologies, expanded offerings, enhanced market access, improved service support, and accelerated menu expansion.
• Suppliers and Other Counterparties: Risk of disruption to business, contractual, and operational relationships due to the pendency of the proposed transaction.

Next Steps

• Completion of the transaction around the end of the first quarter of calendar year 2026.
• Obtaining required regulatory approvals.
• Obtaining Waters shareholder approval.
• Satisfaction of other customary closing conditions.
• Filing of relevant materials with the SEC, including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo.
• BD expects to share more information regarding 'New BD' and its go-forward strategy, innovation pipeline, and longer-term financial outlook closer to the completion of this transaction.

Key Dates

Recommendation

Keywords

Medical technology, Life science, Diagnostics, Merger, Acquisition, Spin-off, Reverse Morris Trust, Becton Dickinson, Waters Corporation, Healthcare, Biotechnology, Financial reporting, Synergies, EBITDA, Revenue growth, EPS accretion, Corporate strategy